Verastem Inc (NASDAQ:VSTM) Short Interest Down 6.5% in December

Share on StockTwits

Verastem Inc (NASDAQ:VSTM) was the target of a significant decline in short interest in December. As of December 31st, there was short interest totalling 12,290,000 shares, a decline of 6.5% from the December 15th total of 13,150,000 shares. Approximately 18.1% of the company’s stock are short sold. Based on an average daily volume of 2,260,000 shares, the short-interest ratio is presently 5.4 days.

VSTM opened at $1.93 on Wednesday. The stock has a market capitalization of $130.85 million, a PE ratio of -1.41 and a beta of 2.97. The firm’s fifty day moving average price is $1.41 and its 200 day moving average price is $1.30. The company has a debt-to-equity ratio of 6.49, a current ratio of 5.47 and a quick ratio of 5.46. Verastem has a 12-month low of $0.83 and a 12-month high of $3.68.

Verastem (NASDAQ:VSTM) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.07. The firm had revenue of $9.03 million for the quarter, compared to analysts’ expectations of $9.20 million. Verastem had a negative net margin of 809.25% and a negative return on equity of 160.88%. On average, equities research analysts forecast that Verastem will post -1.85 earnings per share for the current fiscal year.

A number of research analysts have recently commented on VSTM shares. ValuEngine raised shares of Verastem from a “hold” rating to a “buy” rating in a research report on Friday, January 3rd. Zacks Investment Research cut shares of Verastem from a “buy” rating to a “hold” rating in a research report on Wednesday, January 1st. Finally, HC Wainwright reissued a “buy” rating and set a $2.50 target price on shares of Verastem in a research report on Thursday, January 9th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $5.46.

A number of institutional investors and hedge funds have recently bought and sold shares of VSTM. Morgan Stanley raised its holdings in Verastem by 175.1% in the second quarter. Morgan Stanley now owns 467,873 shares of the biopharmaceutical company’s stock valued at $706,000 after acquiring an additional 297,778 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in Verastem by 467.3% during the second quarter. Price T Rowe Associates Inc. MD now owns 258,300 shares of the biopharmaceutical company’s stock valued at $390,000 after purchasing an additional 212,772 shares during the last quarter. Jane Street Group LLC bought a new stake in Verastem during the second quarter valued at $286,000. Paloma Partners Management Co increased its stake in Verastem by 366.3% during the second quarter. Paloma Partners Management Co now owns 208,400 shares of the biopharmaceutical company’s stock valued at $315,000 after purchasing an additional 163,711 shares during the last quarter. Finally, A.R.T. Advisors LLC bought a new stake in Verastem during the second quarter valued at $204,000. 29.53% of the stock is currently owned by hedge funds and other institutional investors.

Verastem Company Profile

Verastem, Inc, a biopharmaceutical company, focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.

Recommended Story: New Google Finance Tool and Screening Stocks

Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.